Organogenesis Hldgs Q1 2024 Adj EPS $(0.01) Beats $(0.03) Estimate, Sales $109.976M Beat $101.050M Estimate
Portfolio Pulse from Benzinga Newsdesk
Organogenesis Holdings (ORGO) reported Q1 2024 adjusted EPS of $(0.01), surpassing the $(0.03) estimate, with sales of $109.976M exceeding the $101.050M forecast. This represents a 2.17% increase in sales compared to the same period last year.
May 09, 2024 | 9:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Organogenesis Holdings reported a better-than-expected Q1 2024 EPS and sales, indicating a positive performance trend.
Beating both EPS and sales estimates typically signals strong company performance and operational efficiency, which can positively influence investor sentiment and potentially lead to a short-term stock price increase.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100